Volume 77, Issue 6_Suppl
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


The past few years have witnessed the appearance of public-private partnerships and a significant increase of resources devoted to the development of malaria vaccines. Lessons have been learned on different approaches to the clinical development plan for a vaccine candidate, including different clinical trial phases and endpoints and methods to conduct them. Improved understanding of mechanisms underlying naturally acquired immunity, definitions of surrogate markers of protection, including improved assays and animal models, and strengthened capacity in malaria-endemic countries to conduct clinical trials would accelerate the development of malaria vaccines. We are closer to having a first-generation vaccine being registered. The impact of this vaccine and subsequent products will need to be evaluated under program conditions in the context of comprehensive malaria control activities. Deployment of a safe and effective malaria vaccine administered in early childhood could become a major public health tool, particularly in sub-Saharan Africa.


Article metrics loading...

Loading full text...

Full text loading...



  1. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW, 2004. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 4 : 327–336.
  2. Breman JG, 2001. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64 : 1–11.
  3. World Health Organization, 2006. Candidate Malaria Vaccines in Pre-Clinical Development. Geneva: World Health Organization. Available from http://www.who.int/vaccine_research/documents/RainbowTablePreclinical_December2006.pdf.
  4. World Health Organization, 2006. Candidate Malaria Vaccines in Clinical Development. Geneva, World Health Organization. Available from http://www.who.int/vaccine_research/documents/RainbowTable_ClinicalTrials_December2006.pdf.
  5. Reed ZH, Friede M, Kieny MP, 2006. Malaria vaccine development: progress and challenges. Curr Mol Med 6 : 231–245.
  6. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M, 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 336 : 86–91.
  7. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, LaChance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M, 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 171 : 1576–1585.
  8. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, Hall T, Krzych U, Delchambre M, Voss G, Dowler MG, Palensky J, Wittes J, Cohen J, Ballou WR, 2001. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis. 183 : 640–647.
  9. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T, 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 : 1927–1934.
  10. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J, 2004. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364 : 1411–1420.
  11. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR, 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366 : 2012–2018.
  12. World Health Organization, 1997. Guidelines for the Evaluation of Plasmodium falciparum Vaccines in Populations Exposed to Natural Infection. Geneva: World Health Organization.
  13. Greenwood B, 2005. Malaria vaccines. Evaluation and implementation. Acta Trop 95 : 298–304.
  14. The Gambia Hepatitis Study Group, 1987. The Gambia hepatitis intervention study. Cancer Res 47 : 5782–5787.
  15. Greenwood B, Alonso P, 2002. Malaria vaccine trials. Chem Immunol 80 : 366–395.
  16. Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J, 2005. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 23 : 2243–2250.
  17. Duffy MF, Maier AG, Byrne TJ, Marty AJ, Elliott SR, O’Neill MT, Payne PD, Rogerson SJ, Cowman AF, Crabb BS, Brown GV, 2006. VAR2CSA is the principal ligand for chondroitin sulfate A in two allogeneic isolates of Plasmodium falciparum. Mol Biochem Parasitol 148 : 117–124.
  18. Salanti A, Dahlback M, Turner L, Nielsen MA, Barfod L, Magistrado P, Jensen AT, Lavstsen T, Ofori MF, Marsh K, Hviid L, Theander TG, 2004. Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med 200 : 1197–1203.
  19. Viebig NK, Gamain B, Scheidig C, Lepolard C, Przyborski J, Lanzer M, Gysin J, Scherf A, 2005. A single member of the Plasmodium falciparum var multigene family determines cytoadhesion to the placental receptor chondroitin sulphate A. EMBO Rep 6 : 775–781.
  20. Obaro SK, Pugatch D, Luzuriaga K, 2004. Immunogenicity and efficacy of childhood vaccines in HIV-1-infected children. Lancet Infect Dis 4 : 510–518.
  21. Schellenberg JR, Smith T, Alonso PL, Hayes RJ, 1994. What is clinical malaria? Finding case definitions for field research in highly endemic areas. Parasitol Today 10 : 439–442.
  22. Smith T, Schellenberg JA, Hayes R, 1994. Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med 13 : 2345–2358.
  23. Alonso PL, Aponte JJ, 2002. Field trials. Doolan DL, ed. Methods in Molecular Medicine. Volume 72: Malaria Methods and Protocols. Totowa, NJ: Humana Press, Inc., 607–616.
  24. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, Fosiko NG, Lewallen S, Liomba NG, Molyneux ME, 2004. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 10 : 143–145.
  25. Todd JE, de Francisco A, O’Dempsey TJ, Greenwood BM, 1994. The limitations of verbal autopsy in a malaria-endemic region. Ann Trop Paediatr 14 : 31–36.
  26. Snow RW, Armstrong JR, Forster D, Winstanley MT, Marsh VM, Newton CR, Waruiru C, Mwangi I, Winstanley PA, Marsh K, 1992. Childhood deaths in Africa: uses and limitations of verbal autopsies. Lancet 340 : 351–355.
  27. Mendis K, Sina BJ, Marchesini P, Carter R, 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 (Suppl 1-2): 97–106.
  28. Higgs ES, Sina B, 2005. Plasmodium vivax vaccine research: steps in the right direction. Am J Trop Med Hyg 73 : 1–2.
  29. World Health Organization, 2003. Report of the First Meeting of the WHO Malaria Vaccine Advisory Committee (MALVAC). April 2003. Geneva: World Health Organization.
  30. Malkin E, Dubovsky F, Moree M, 2006. Progress towards the development of malaria vaccines. Trends Parasitol 22 : 292–295.
  31. Moree M, Ewart S, 2004. Policy challenges in malaria vaccine introduction. Am J Trop Med Hyg 71 : 248–252.

Data & Media loading...

  • Received : 21 Aug 2006
  • Accepted : 22 Sep 2007

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error